Literature DB >> 23233484

Knockdown of PAK4 or PAK1 inhibits the proliferation of mutant KRAS colon cancer cells independently of RAF/MEK/ERK and PI3K/AKT signaling.

Hana Tabusa1, Teresa Brooks, Andrew J Massey.   

Abstract

The p21-activated kinase (PAK) serine/threonine kinases are important effectors of the small GTPases Rac and Cdc42, and play significant roles in controlling cell growth, motility, and transformation. Knockdown of PAK4 or PAK1 inhibited the proliferation of mutant KRAS or BRAF colon cancer cells in vitro. Dependence on PAK4 or PAK1 protein for colon cancer cell proliferation was independent of PAK4 or PAK1 protein expression levels. Mutant KRAS HCT116 colorectal cells were the most sensitive to PAK4 or PAK1 knockdown resulting in the potent inhibition of anchorage-dependent and -independent proliferation as well as the formation and proliferation of HCT116 colon cancer spheroids. This inhibition of proliferation did not correlate with inhibition of RAF/MEK/ERK or PI3K/AKT signaling. In HCT116 cells, knockdown of PAK4 or PAK1 caused changes to the actin cytoskeleton resulting in reduced basal spread and cell elongation and increased cell rounding. These cytoskeletal rearrangements seemed to be independent of LIMK/cofilin/paxillin phosphorylation. PAK4 or PAK1 knockdown initially induced growth arrest in HCT116 cells followed by cell death at later time points. Inhibition of the antiapoptotic proteins Bcl-2 and Bcl-X(L) with the pharmacologic inhibitor ABT-737 increased effector caspase activation and apoptosis, and reduced cell survival with PAK4 or PAK1 knockdown. These results support a role for the PAKs in the proliferation of mutant KRAS-driven colorectal carcinoma cells via pathways not involving RAF/MEK/ERK and PI3K/AKT signaling.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23233484     DOI: 10.1158/1541-7786.MCR-12-0466

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  52 in total

Review 1.  Group II p21-activated kinases as therapeutic targets in gastrointestinal cancer.

Authors:  Yang-Guang Shao; Ke Ning; Feng Li
Journal:  World J Gastroenterol       Date:  2016-01-21       Impact factor: 5.742

Review 2.  Signaling, Regulation, and Specificity of the Type II p21-activated Kinases.

Authors:  Byung Hak Ha; Elizabeth M Morse; Benjamin E Turk; Titus J Boggon
Journal:  J Biol Chem       Date:  2015-04-08       Impact factor: 5.157

Review 3.  p21-Activated Kinases in Thyroid Cancer.

Authors:  Luis Bautista; Christina M Knippler; Matthew D Ringel
Journal:  Endocrinology       Date:  2020-08-01       Impact factor: 4.736

Review 4.  The cell survival pathways of the primordial RNA-DNA complex remain conserved in the extant genomes and may function as proto-oncogenes.

Authors:  J G Sinkovics
Journal:  Eur J Microbiol Immunol (Bp)       Date:  2015-03-26

5.  p21-activated kinase 4 critically regulates melanogenesis via activation of the CREB/MITF and β-catenin/MITF pathways.

Authors:  Cheong-Yong Yun; Soon-Tae You; Jin-Hwa Kim; Jin H Chung; Sang-Bae Han; Eun-Young Shin; Eung-Gook Kim
Journal:  J Invest Dermatol       Date:  2015-01-05       Impact factor: 8.551

6.  Gastrointestinal hormones/neurotransmitters and growth factors can activate P21 activated kinase 2 in pancreatic acinar cells by novel mechanisms.

Authors:  Bernardo Nuche-Berenguer; R T Jensen
Journal:  Biochim Biophys Acta       Date:  2015-05-12

7.  Systems-wide analysis of K-Ras, Cdc42, and PAK4 signaling by quantitative phosphoproteomics.

Authors:  Florian Gnad; Amy Young; Wei Zhou; Karen Lyle; Christy C Ong; Matthew P Stokes; Jeffrey C Silva; Marcia Belvin; Lori S Friedman; Hartmut Koeppen; Audrey Minden; Klaus P Hoeflich
Journal:  Mol Cell Proteomics       Date:  2013-04-22       Impact factor: 5.911

Review 8.  PAK signalling during the development and progression of cancer.

Authors:  Maria Radu; Galina Semenova; Rachelle Kosoff; Jonathan Chernoff
Journal:  Nat Rev Cancer       Date:  2014-01       Impact factor: 60.716

9.  Functional role and therapeutic targeting of p21-activated kinase 4 in multiple myeloma.

Authors:  Mariateresa Fulciniti; Joaquin Martinez-Lopez; William Senapedis; Stefania Oliva; Rajya Lakshmi Bandi; Nicola Amodio; Yan Xu; Raphael Szalat; Annamaria Gulla; Mehmet K Samur; Aldo Roccaro; Maria Linares; Michele Cea; Erkan Baloglu; Christian Argueta; Yosef Landesman; Sharon Shacham; Siyuan Liu; Monica Schenone; Shiaw-Lin Wu; Barry Karger; Rao Prabhala; Kenneth C Anderson; Nikhil C Munshi
Journal:  Blood       Date:  2017-01-17       Impact factor: 22.113

10.  Targeting super-enhancer-associated oncogenes in oesophageal squamous cell carcinoma.

Authors:  Yan-Yi Jiang; De-Chen Lin; Anand Mayakonda; Masaharu Hazawa; Ling-Wen Ding; Wen-Wen Chien; Liang Xu; Ye Chen; Jin-Fen Xiao; William Senapedis; Erkan Baloglu; Deepika Kanojia; Li Shang; Xin Xu; Henry Yang; Jeffrey W Tyner; Ming-Rong Wang; H Phillip Koeffler
Journal:  Gut       Date:  2016-05-10       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.